Search research articles
Contact Us
Filters
Showing results (11-20 of 112) with videos related to
Page
of 12
Sort By:
JAMA
|
August 21, 2024
Surrogate Markers and Clinical Outcomes-Reply
Joshua D Wallach, Reshma Ramachandran, Joseph S Ross
The New England Journal of Medicine
|
December 8, 2025
Enhancing FDA Drug-Safety Surveillance - Beyond Releasing Daily Adverse-Event Data
Joshua D Wallach, Joseph S Ross, Reshma Ramachandran
Clinical Trials (London, England)
|
June 7, 2018
The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
Joshua D Wallach, Joseph S Ross, Huseyin Naci
JAMA
|
July 21, 2018
Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
Jeremy Puthumana, Joshua D Wallach, Joseph S Ross
JAMA
|
November 21, 2018
Breakthrough Therapy Designation for New Drugs-Reply
Jeremy Puthumana, Joshua D Wallach, Joseph S Ross
Journal of Clinical Epidemiology
|
October 19, 2017
Research, regulatory, and clinical decision-making: the importance of scientific integrity
Joshua D Wallach, Gregg S Gonsalves, Joseph S Ross
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2024
Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation study
Xiaoting Shi, Joshua D Wallach, Xiaomei Ma, et al.
JAMA Internal Medicine
|
February 12, 2024
Hypothetical Assessments of Trial Emulations-Reply
Guneet S Janda, Joshua D Wallach, Joseph S Ross
Cancer Medicine
|
November 7, 2024
Autoimmune Diseases and Risk of Non-Hodgkin Lymphoma: A Mendelian Randomisation Study
Xiaoting Shi, Joshua D Wallach, Xiaomei Ma, et al.
Plos Biology
|
November 21, 2018
Reproducible research practices, transparency, and open access data in the biomedical literature, 2015-2017
Joshua D Wallach, Kevin W Boyack, John P A Ioannidis
Page
of 12
Search research articles
Search
Showing results (11-20 of 112) with videos related to
Sort By:
Page
of 12
JAMA
|
August 21, 2024
Surrogate Markers and Clinical Outcomes-Reply
Joshua D Wallach, Reshma Ramachandran, Joseph S Ross
The New England Journal of Medicine
|
December 8, 2025
Enhancing FDA Drug-Safety Surveillance - Beyond Releasing Daily Adverse-Event Data
Joshua D Wallach, Joseph S Ross, Reshma Ramachandran
Clinical Trials (London, England)
|
June 7, 2018
The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
Joshua D Wallach, Joseph S Ross, Huseyin Naci
JAMA
|
July 21, 2018
Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
Jeremy Puthumana, Joshua D Wallach, Joseph S Ross
JAMA
|
November 21, 2018
Breakthrough Therapy Designation for New Drugs-Reply
Jeremy Puthumana, Joshua D Wallach, Joseph S Ross
Journal of Clinical Epidemiology
|
October 19, 2017
Research, regulatory, and clinical decision-making: the importance of scientific integrity
Joshua D Wallach, Gregg S Gonsalves, Joseph S Ross
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2024
Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation study
Xiaoting Shi, Joshua D Wallach, Xiaomei Ma, et al.
JAMA Internal Medicine
|
February 12, 2024
Hypothetical Assessments of Trial Emulations-Reply
Guneet S Janda, Joshua D Wallach, Joseph S Ross
Cancer Medicine
|
November 7, 2024
Autoimmune Diseases and Risk of Non-Hodgkin Lymphoma: A Mendelian Randomisation Study
Xiaoting Shi, Joshua D Wallach, Xiaomei Ma, et al.
Plos Biology
|
November 21, 2018
Reproducible research practices, transparency, and open access data in the biomedical literature, 2015-2017
Joshua D Wallach, Kevin W Boyack, John P A Ioannidis
Page
of 12